OOIR: Observatory of International Research

Papers

(The TQCC of EJNMMI Research is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregates	48
Imaging tumor and ascites-associated macrophages in a mouse model of metastatic ovarian cancer	43
18 F-Choline-PET/CT for non-FDG-avid salivary gland cancer: a preliminary report	37
Change in brain amyloid load and cognition in patients with amnestic mild cognitive impairment: a 3-year follow-up study	33
[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study	31
Influence of corticosteroid treatment on CXCR4 expression in DLBCL	29
Adenosine-induced splenic switch-off on [15O]H2O PET perfusion for the assessment of vascular vasodilatation	27
[18F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis	27
Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, n	27
Cardiometabolic disorders affect myocardial [18F]fluorodeoxyglucose uptake– impact on diagnostic PET/CT imaging	26
18F-FDG PET/CT-based deep learning radiomics predicts 5-years disease-free survival after failure to achieve pathologic complete response to neoadjuvant chemotherapy in breast cancer	25
Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods	25
Hypometabolism and atrophy patterns associated with Niemann-Pick type C	25
Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression	24
All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful	23
Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling	22
Quantification of [99mTc]Tc-HDP bone SPECT/CT: can we improve the body weight based standardized uptake value with a more robust normalization?	22
Preliminary mechanistic insights of a brain-penetrant microtubule imaging PET ligand in a tau-knockout mouse model	21
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A	20
Test-retest repeatability of quantitative organ and tissue uptake using 20-minute dynamic multiparametric whole-body [18F]FDG PET/CT in patients with type 2 diabetes	20
First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study	20
Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases	20
Association of white matter injury and neuroinflammation in the post-acute phase after ischemic stroke using [18F]FEPPA-PET/MRI	19
The value of radiomics based on 2-[18 F]FDG PET/CT in predicting WHO/ISUP grade of clear cell renal cell carcinoma	19
Quantitative renal [99mTc]DMSA imaging predicts urinary [99mTc]DMSA excretion in patients with chronic kidney disease	19

Radiation dosimetry and fasting-dependent hepatobiliary clearance of the VAChT-specific PET radioligand 18F-VAT in humans	19
Autoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue	18
The effects of novel macrocyclic chelates on the targeting properties of the 68Ga-labeled Gastrin releasing peptide receptor antagonist RM2	18
A biorthogonal chemistry approach for high-contrast antibody imaging of lymphoma at early time points	18
Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval	18
Lung shunt fraction calculation using 99mTc-MAA SPECT/CT imaging for 90Y microsphere selective internal radiation therapy of liver tumors	18
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue	16
Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation	16
Engineering a modular 44Ti/44Sc generator: eluate evaluation in preclinical models and estimation of human radiation dosimetry	16
PET imaging of GABAA receptors in pancreatic islets by [11C]flumazenil	16
First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor	15
Reduced splenic uptake of [68Ga]Ga-Pentixafor following first-line chemotherapy is associated with poor prognosis in patients with newly diagnosed multiple myeloma	15
Reorganization of brain connectivity in post-COVID condition: a 18F-FDG PET study	14
Semi-quantitative indices of 2-[18F]FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response	14
TCP post-radioembolization and TCP post-EBRT in HCC are similar and can be predicted using the in vitro radiosensitivity	14
A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making	14
Prognostic value of 18F-FDG PET/CT-based radiomics combining dosiomics and dose volume histogram for head and neck cancer	13
cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer	13
Quantification in respiratory-gated PET acquisition: can data-driven methods replace device-based systems?—a comparative and retrospective study	13
[18F]FDOPA PET/CT is superior to [68Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytoma	13
Ultrasensitive detection of uveal melanoma using [18F]AlF-NOTA-PRGD2 PET imaging	13
The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors	12
Molecular imaging in hypertrophic cardiomyopathy: an exploratory study with 2-[18F]FDG and [13N]NH3	12
Fc-engineered monoclonal antibodies to reduce off-target liver uptake	12
Correction: [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism	12
Magnetic resonance spectroscopy for enhanced multiparametric MRI characterization of [18F]FET PET-negative gliomas	12
Effect of the identification group size and image resolution on the diagnostic performance of metabolic Alzheimer’s disease-related pattern	12
Distinguishing lymphoma from benign lymph node diseases in fever of unknown origin using PET/CT radiomics	11
Molecular imaging of fibroblast activation in multiple non-ischemic cardiomyopathies	11
A study method using early dynamic acquisition of [18F]fluorodopa positron emission tomography for the differential diagnosis between progression and radionecrosis of brain metastases after radiothera	11
Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients	11
Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes	11
Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma	11
In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET	11
A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides	11
Correction to: Biokinetics, dosimetry and radiation risk in infants after 99mTc-MAG3 scans	11
Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer	11
Biphasic contrast-enhanced [18F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer	10
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases	10
[18F]FDG PET-MR characterization of aortitis in the IL1rn−/− mouse model of giant-cell arteritis	10
Spatial distribution of fractionally administered holmium microspheres in non-tumorous human liver tissue: how livers survive transarterial radioembolisation	10
3′-deoxy-3′-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy	10
A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors	10
68Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism	10
Dopamine transporter single-photon emission computed tomography-derived radiomics signature for detecting Parkinson’s disease	10
Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in patients and clinically realistic simulations	10
[18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer’s disease pathology in APP/PS1 mice	10
The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study	10
Characterization of in vivo binding kinetics and non-displaceable binding of [18F]SynvesT-1 in the rat brain	10
Reduced hematopoietic-inflammatory response and worse outcomes in patients with recurrent myocardial infarction in comparison with primary myocardial infarction	10

Imaging bone turnover assessment through volumetric density-adjusted standardized uptake value using quantitative bone SPECT/CT in osteoporosis	10
Phantom and clinical evaluation of the effect of a new Bayesian penalized likelihood reconstruction algorithm (HYPER Iterative) on 68Ga-DOTA-NOC PET/CT image quality	10
Characterisation of a novel [18F]FDG brain PET database and combination with a second database for optimising detection of focal abnormalities, using focal cortical dysplasia as an example	9
Effect of radiation therapy on lymph node fluorescence in head and neck squamous cell carcinoma after intravenous injection of indocyanine green: a prospective evaluation	9
Exploring the impact of PEGylation on pharmacokinetics: a size-dependent effect of polyethylene glycol on prostate-specific membrane antigen inhibitors	9
A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial	9
Light up heart-type fatty acid binding protein (FABP3) with a novel fluorine-18 labelled selective FABP3 ligand	9
68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study	9
Accuracy of dynamic sentinel lymph node biopsy for inguinal lymph node staging in cN0 penile cancer	9
Preclinical evaluation of Affibody molecule for PET imaging of human pancreatic islets derived from stem cells	9
Evaluation of the theranostic potential of [64Cu]CuCl2 in glioblastoma spheroids	9
There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography	9
Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study	9
Development of [89Zr]Zr-hCD103.Fab01A and [68Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET	9
Impact of brain segmentation methods on regional metabolism quantification in 18F-FDG PET/MR analysis	9
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours	9
AI may help to predict thyroid nodule malignancy based on radiomics features from [18F]FDG PET/CT	8
Preclinical evaluation of glycan-targeting monoclonal antibodies for bimodal near-infrared fluorescence and photoacoustic imaging of gastrointestinal cancers	8
Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells	8
A histogram of [18F]BBPA PET imaging differentiates non-neoplastic lesions from malignant brain tumors	8
Metabolic phenotyping of hand automatisms in mesial temporal lobe epilepsy	8
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): methodological application in [18F]-FDOPA PET imaging	8
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model	8
Effect of cerebral sinus venous thrombosis and its location on cerebral blood flow: a [15O]water PET study in acute stroke patients compared to healthy volunteers	8
Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)	8
Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors	8
Myocardial glucose suppression may interfere with the detection of inflammatory cells with FDG-PET as suggested in a canine model of myocardial infarction	8
Feasibility of a drop-in γ-probe for radioguided sentinel lymph detection in early-stage cervical cancer	8
Response to letter: More fat, less migration: breast density as a predictor of sentinel lymph node non-visualization in breast cancer	7
Heteroaryl derivatives of suvorexant as OX1R selective PET ligand candidates: Cu-mediated 18F-fluorination of boroxines, in vitro and initial in vivo evaluation	7
External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients	7
Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery	7
The remodeling of metabolic brain pattern in patients with extracranial diffuse large B-cell lymphoma	7
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study	7
The intra- and interobserver variability of PSMA-expression scores in patients with primary prostate cancer	7
PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer	7
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy	7
Sex correction improves the accuracy of clinical dopamine transporter imaging	7
Evaluation of [11C]UCB-A positron emission tomography in human brains	7
Kinetics of the amino acid uptake tracer O-(2-[18F]fluoroethyl)-L-tyrosine (FET) in human brain	7
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates	7
The effect of butylscopolamine on [18F]FDG uptake in the gastrointestinal tract is negligible and regionally variable	7
Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma	7
18F-ASEM PET/MRI targeting alpha7-nicotinic acetylcholine receptor can reveal skeletal muscle denervation	7
The assessment of left ventricular volume and function in gated small animal 18F-FDG PET/CT imaging: a comparative study of three commercially available software tools	7
Clinical significance of diffuse [18F] AlF-NOTA-FAPI-04 uptake in the thyroid on PET/CT imaging	7
Clinical feasibility and impact of data-driven respiratory motion compensation studied in 200 whole-body 18F-FDG PET/CT scans	7